Skip Navigation


European Heart Journal Advance Access originally published online on September 30, 2008
European Heart Journal 2008 29(23):2877-2885; doi:10.1093/eurheartj/ehn419
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/23/2877    most recent
ehn419v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lordkipanidzé, M.
Right arrow Articles by Diodati, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lordkipanidzé, M.
Right arrow Articles by Diodati, J. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients

Marie Lordkipanidzé1,2,3,{dagger}, Chantal Pharand1,2,3,{dagger}, Thuy Anh Nguyen1,3, Erick Schampaert2,4,5, Donald A. Palisaitis2,4,5 and Jean G. Diodati2,4,5,*

1 Faculty of Pharmacy, Université de Montréal, Montréal, Canada
2 Research Center, Hôpital du Sacré-Cœur de Montréal, 5400, boul. Gouin ouest, Montréal, Québec, Canada H4J 1C5
3 Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, 5400, boul. Gouin ouest, Montréal, Québec, Canada H4J 1C5
4 Faculty of Medicine, Université de Montréal, Montréal, Canada
5 Division of Cardiology, Hôpital du Sacré-Cœur de Montréal, 5400, boul. Gouin ouest, Montréal, Québec, Canada H4J 1C5

Received 14 March 2008; revised 19 August 2008; accepted 28 August 2008; online publish-ahead-of-print 30 September 2008.

* Corresponding author. Tel: +1 514 338 2200, Fax: +1 514 338 2694, Email: jean.gino.diodati{at}umontreal.ca

See page 2833 for the editorial comment on this article (doi:10.1093/eurheartj/ehn494)

Aims: We investigated the comparability of platelet function tests in quantifying platelet inhibition achieved by clopidogrel.

Methods and results: This pre-specified substudy of a randomized, double-blind trial included 116 patients with stable coronary artery disease requiring diagnostic angiography. Patients received clopidogrel for 1 (300 or 600 mg) or 7 days (300 + 75 or 150 mg daily) before the procedure. Blood samples obtained before clopidogrel initiation and before diagnostic coronary angiography were assayed using light transmission aggregometry [adenosine diphosphate (ADP) 5 and 20 µM as the agonist], whole-blood aggregometry (ADP 5 and 20 µM), PFA-100® (Collagen-ADP cartridge), and VerifyNow® P2Y12. Although all assays studied were found sensitive to clopidogrel ingestion, none could distinguish categorically between patients who had, or not, ingested clopidogrel. Agreement between assays to identify patients with insufficient inhibition of platelet aggregation by clopidogrel was low.

Conclusion: The assessment of platelet function inhibition by clopidogrel is highly test-specific. Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable. At present, platelet function testing evaluating clopidogrel efficacy cannot be recommended in routine clinical practice.

Key Words: Platelet function testing • Platelet aggregation • Platelet analyzers • Clopidogrel • Responsiveness

{dagger} The first two authors have contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The challenge of monitoring platelet response after clopidogrel
Victor L. Serebruany and Shinya Goto
EHJ 2008 29: 2833-2834. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
F. J. Pastor-Perez, J. Rivera, M. L. Lozano, and F. Marin
Does the Holy Grail escape us again?
Eur. Heart J., May 1, 2009; 30(9): 1152 - 1152.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
V. L. Serebruany and S. Goto
The challenge of monitoring platelet response after clopidogrel
Eur. Heart J., December 1, 2008; 29(23): 2833 - 2834.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.